TEVA-ERLOTINIB 150 MG
ERLOTINIB (ERLOTINIB HYDROCHLORIDE) : 150 MG · DIN 02377713 · TEVA CANADA LIMITED
Health Canada status: MARKETED
What is TEVA-ERLOTINIB?
TEVA-ERLOTINIB 150 MG contains ERLOTINIB (ERLOTINIB HYDROCHLORIDE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02377713, held by TEVA CANADA LIMITED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Dec-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02377713 |
|---|---|
| Brand name | TEVA-ERLOTINIB |
| Generic / active ingredient | ERLOTINIB (ERLOTINIB HYDROCHLORIDE) : 150 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 150 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01EB02 ERLOTINIB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Dec-2014 |
| Original market date | 2014-12-08 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code L01EB02 ERLOTINIB. 7 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-ERLOTINIB | 100 MG | TABLET | APOTEX INC | MARKETED | DIN 02461870 |
| APO-ERLOTINIB | 150 MG | TABLET | APOTEX INC | MARKETED | DIN 02461889 |
| APO-ERLOTINIB | 25 MG | TABLET | APOTEX INC | MARKETED | DIN 02461862 |
| PMS-ERLOTINIB | 150 MG | TABLET | PHARMASCIENCE INC | MARKETED | DIN 02454394 |
| TEVA-ERLOTINIB | 100 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02377705 |
| TEVA-ERLOTINIB | 25 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02377691 |
| NAT-ERLOTINIB | 100 MG | TABLET | NATCO PHARMA (CANADA) INC | DORMANT | DIN 02483920 |
| NAT-ERLOTINIB | 150 MG | TABLET | NATCO PHARMA (CANADA) INC | DORMANT | DIN 02483939 |
| NAT-ERLOTINIB | 25 MG | TABLET | NATCO PHARMA (CANADA) INC | DORMANT | DIN 02483912 |
| PMS-ERLOTINIB | 100 MG | TABLET | PHARMASCIENCE INC | DORMANT | DIN 02454386 |
Who else supplies ERLOTINIB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ERLOTINIB appears in 129 registered pack listings across 14 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.